Cargando…

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study

PURPOSE: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab 0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort. PATIENTS AND METHODS: This Belgian (BE) cohort of the 5-year global observational LUMINOUS study included 229 patients with nA...

Descripción completa

Detalles Bibliográficos
Autores principales: Leys, Anita M, Ramboer, Eva, Favreau, Mérédis, Denhaerynck, Kris, MacDonald, Karen, Abraham, Ivo, Brié, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277576/
https://www.ncbi.nlm.nih.gov/pubmed/32581505
http://dx.doi.org/10.2147/OPTH.S242547
_version_ 1783543150289092608
author Leys, Anita M
Ramboer, Eva
Favreau, Mérédis
Denhaerynck, Kris
MacDonald, Karen
Abraham, Ivo
Brié, Heidi
author_facet Leys, Anita M
Ramboer, Eva
Favreau, Mérédis
Denhaerynck, Kris
MacDonald, Karen
Abraham, Ivo
Brié, Heidi
author_sort Leys, Anita M
collection PubMed
description PURPOSE: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab 0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort. PATIENTS AND METHODS: This Belgian (BE) cohort of the 5-year global observational LUMINOUS study included 229 patients with nAMD. Outcomes included visual acuity (VA), central retinal thickness (CRT) and safety. RESULTS: The mean age was 79.5±7.7 years. The majority of patients (67.7%) were female and all patients were Caucasian. Most patients previously received ranibizumab with only 17.5% of patients being treatment-naïve. The injection frequency declined over time irrespective of prior treatment status (p<0.0001), with treatment-naïve eyes receiving a mean of 4.2±2.9 yearly injections and prior-ranibizumab eyes 3.6±2.7. Regression analysis confirmed first-year VA increases for treatment-naïve eyes (p=0.002) followed by a slight decrease of −1.8 letters per year. For prior-ranibizumab eyes, the visual changes over 1 year were statistically non-significant (p=0.90) but declined slightly after year one (p<0.0001). Anatomically, the CRT of treatment-naïve eyes decreased over time from baseline (p<0.0001), whereas the CRT of prior-ranibizumab eyes remained stable (p=0.43). No new safety findings were identified. CONCLUSION: LUMINOUS-BE reconfirms the well-characterized benefit-risk profile of ranibizumab for nAMD treatment. The observed low injection frequency reflects a need for more rigorous treatment in real-world settings. CLINICAL TRIAL REGISTRATION: NCT01318941.
format Online
Article
Text
id pubmed-7277576
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-72775762020-06-23 Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study Leys, Anita M Ramboer, Eva Favreau, Mérédis Denhaerynck, Kris MacDonald, Karen Abraham, Ivo Brié, Heidi Clin Ophthalmol Original Research PURPOSE: To evaluate long-term, real-world treatment patterns and outcomes of ranibizumab 0.5 mg for neovascular age-related macular degeneration (nAMD) in a Belgian cohort. PATIENTS AND METHODS: This Belgian (BE) cohort of the 5-year global observational LUMINOUS study included 229 patients with nAMD. Outcomes included visual acuity (VA), central retinal thickness (CRT) and safety. RESULTS: The mean age was 79.5±7.7 years. The majority of patients (67.7%) were female and all patients were Caucasian. Most patients previously received ranibizumab with only 17.5% of patients being treatment-naïve. The injection frequency declined over time irrespective of prior treatment status (p<0.0001), with treatment-naïve eyes receiving a mean of 4.2±2.9 yearly injections and prior-ranibizumab eyes 3.6±2.7. Regression analysis confirmed first-year VA increases for treatment-naïve eyes (p=0.002) followed by a slight decrease of −1.8 letters per year. For prior-ranibizumab eyes, the visual changes over 1 year were statistically non-significant (p=0.90) but declined slightly after year one (p<0.0001). Anatomically, the CRT of treatment-naïve eyes decreased over time from baseline (p<0.0001), whereas the CRT of prior-ranibizumab eyes remained stable (p=0.43). No new safety findings were identified. CONCLUSION: LUMINOUS-BE reconfirms the well-characterized benefit-risk profile of ranibizumab for nAMD treatment. The observed low injection frequency reflects a need for more rigorous treatment in real-world settings. CLINICAL TRIAL REGISTRATION: NCT01318941. Dove 2020-06-02 /pmc/articles/PMC7277576/ /pubmed/32581505 http://dx.doi.org/10.2147/OPTH.S242547 Text en © 2020 Leys et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Leys, Anita M
Ramboer, Eva
Favreau, Mérédis
Denhaerynck, Kris
MacDonald, Karen
Abraham, Ivo
Brié, Heidi
Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study
title Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study
title_full Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study
title_fullStr Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study
title_full_unstemmed Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study
title_short Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUS(TM) Study
title_sort long-term ranibizumab treatment in neovascular age-related macular degeneration: a belgian subanalysis from the global real-world luminous(tm) study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277576/
https://www.ncbi.nlm.nih.gov/pubmed/32581505
http://dx.doi.org/10.2147/OPTH.S242547
work_keys_str_mv AT leysanitam longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy
AT ramboereva longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy
AT favreaumeredis longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy
AT denhaerynckkris longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy
AT macdonaldkaren longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy
AT abrahamivo longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy
AT brieheidi longtermranibizumabtreatmentinneovascularagerelatedmaculardegenerationabelgiansubanalysisfromtheglobalrealworldluminoustmstudy